98-92-0 | Sigma-Aldrich

The Effective Use of Protein Kinase Inhibitors

94 139 92 92 107 85 85 89 90 114 113 90 107 102 97 98 107 JNK1α1/SAPK1c 97 98 96 49 104 96 102 111 101 93 97 108 101 98 92 89 95 91 100 JNK/SAPK1c

The Effective Use of Protein Kinase Inhibitors

94 139 92 92 107 85 85 89 90 114 113 90 107 102 97 98 107 JNK1α1/SAPK1c 97 98 96 49 104 96 102 111 101 93 97 108 101 98 92 89 95 91 100 JNK/SAPK1c

Poster: Purification with Millipore MultiScreen 384SEQ Plates on Beckman-Coulter’s Biomek FX for High Quality Direct Sequencing in High-Throughput Genomics

336.82 98% il12a_1 yq 37.48 371.95 98% il12a_1 yq 37.44 365.39 93% il12a_1 zq 39.78 400.66 98% il12a_1 zq 41.14 383.16 88% il12a_1 zq 44.93 452.26 98% il12a_7-A yq r1 15.65 0 0% il12a_7-A yq r1 0 0 0% il12a

Application Note – N-Boc deprotection

O 92% 93% 92% HN NH S O H N O O O NH2 98% N H OH NH2 98% 90% NH 91% O O NH3

LABORATORY NOTEBOOK ISSUANCE PAGE

tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4

Lab Notebook Guidelines

tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4

LABORATORY NOTEBOOK ISSUANCE PAGE

tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4

LABORATORY NOTEBOOK ISSUANCE PAGE

tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4

High throughput sample preparation for the quantitation of drug compounds in serum samples

Digoxin 93±3% 96±2% 98±3% 94±1% Propranolol 97±2% 98±4% 95±3% 96±2% Taxol 93±3% 92±1% 91±2% 88±2% Testosterone 94±3% 92±2% 91±2% 90±1% Verapamil 95±3% 97±1% 92±2% 98±1% Warfarin 91±3% 93±2%

TC RNA Phosphoramidites

90% 92% 94% 96% 98% 100% DMT-rUtc-AM DMT-rG(ib)tc-AM DMT-rC(ac)tc-AM DMT-rA(bz)tc-AM HPLC Purity Stability in Toluene/Acetonitrile 1:1 / 7 d at 25 ºC 90% 92% 94% 96% 98% 100%

Protocol: Rat/Mouse Ghrelin (Active)

Rat 0 (Basal) 168 -- 181 -- 50 218 100% 233 104% 200 356

Verfication summary-03-0202-00

64.20 6.5 10% 128.41 6.5 5% - 3 1:4 31.31 0.7 2% 125.23 0.7 1% 98% 3 1:8 17.04 0.1 1% 136.34 0.1 0% 106% 3 1:16 7.85 0.3 4% 125.62 0.3 0% 98% HMN108002 3

Verfication summary-03-0202-00

64.20 6.5 10% 128.41 6.5 5% - 3 1:4 31.31 0.7 2% 125.23 0.7 1% 98% 3 1:8 17.04 0.1 1% 136.34 0.1 0% 106% 3 1:16 7.85 0.3 4% 125.62 0.3 0% 98% HMN108002 3

Data Sheet - R5635

1. Wabon, R., et al., FEBS Letters, 118, 47 (1980). 2. Kessler, C., et al., Gene, 92, 1 (1990). 7/98 Sigma brand products are sold

Product Information Sheet - MAK395

Chromophore (nmol/well) 1 0 L 100 L 0 2 2 L 98 L 2 3 4 L 96 L 4 4 6 L 94 L 6 5 8 L 92 L 8 6 10 L 90 L 10

Product Information Sheet - Amine-Stabilized Borane-Tetrahydrofuran Solutions

%) Temp.(CO) 17,619-2 NaBH 4 98 93.6 5 65,039-0 PMP 97 94.9 5 65,041-2 NIMBA 98 94.8 5 17,619-2 NaBH 4 97 90.3 25 65,039-0 PMP 98 96.1 25 65,041-2 NIMBA 98 96.2 25 Cat. No. (1.0M BH 3

Product Information Sheet - I4507

preservative at 0-8°C. REFERENCES: 1. Sigma production. 2. Methods in Enzymology, 184, 167 (1990). Iminobiotin affinity columns. 3. Heney, G. and Orr, G.A., Anal. Biochem., 114, 92-96 (1981). Purification

Data Sheet - A5156

actinomycin D (98% purity) and 49 mg of Mannitol. It is soluble in water at 20 mg/ml. References 1. Merck Index, 12th ed., No. 2867 (1996). 2. Meienhofer, J., J. Am. Chem. Soc., 92, 3771-77 (

Data Sheet - A4262

actinomycin D (98% purity) and 49 mg of Mannitol. It is soluble in water at 20 mg/ml. References 1. Merck Index, 12th ed., No. 2867 (1996). 2. Meienhofer, J., J. Am. Chem. Soc., 92, 3771-77 (

Data Sheet - A1410

actinomycin D (98% purity) and 49 mg of Mannitol. It is soluble in water at 20 mg/ml. References 1. Merck Index, 12th ed., No. 2867 (1996). 2. Meienhofer, J., J. Am. Chem. Soc., 92, 3771-77 (

Actinomycin D (A9415)

actinomycin D (98% purity) and 49 mg of Mannitol. It is soluble in water at 20 mg/ml. References 1. Merck Index, 12th ed., No. 2867 (1996). 2. Meienhofer, J., J. Am. Chem. Soc., 92, 3771-77 (

SARS-Cov2 anti-RBD IgG ELISA

Expected (ng/mL) Observed (ng/mL) Expected 1 100 29.1 29.1 50 14.6 14.2 98% 25 7.3 6.7 92% 12.5 3.6 3.3 90%

Protocol: Human PYY (Total) ELISA Kit - 96-Well Plate

97% 500 511 84% 647 109% F 0 (Basal) 75 -- 78 -- 40 115 100% 114 90% 100 167 92% 167

123-91-1 71-36-3 71-36-3 71-41-0 71-23-8 78-92-2 110-80-5 109-86-4 78-83-1 67-63-0 67-63-0 123-51-3 75-07-0 75-07-0 64-19-7 67-64-1 67-64-1 75-05-8

Evaluation of DNA Extraction and Amplification Protocols

by 35 cycles (92 °C 20 sec, 68 °C 3 min), and a final elongation step of 5 minutes at 68 °C. A p p li ca ti o n N ot es

Detergents Properties and Applications

98854-16-1 85618-21-9 11024-24-1 2190-95-6 871-95-4 9036-19-5 85316-98-9 85261-19-4 85261-20-7 9016-45-9 9003-11-6 8047-15-2 9002-92-0 9002-93-1 9036-19-5 9005-64-5 9005-66-7 9005-65-6 MW (anhydrous) 878

Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease

Pharmacol. Exp. Ther., 289, 926-935 (1999). 92. Lewis, K., et al., Proc. Natl. Acad. Sci. USA, 98, 7570-7575 (2001). 93. Reyes, T.M., et al., Proc. Natl. Acad. Sci. USA, 98, 2843-2848. (2001). 94. Rivier, J.

Product Information Sheet - SE120105

Serum Original Value (ng/ml) Percentage of Recovery 1:2 1:4 1:8 1 2 60 50 102 105 98 97 92 93 References 1. Vanderpump, M.P. et al., The prevalence of hyperprolactinaemia and association

Product Information Sheet-04693124001

incubation with the protease Pancreas extract 0.02 7.8 85 96 Pronase 0.005 7.8 92 98 Thermolysin 0.0005 7.8 98 98 Chymotrypsin 0.0015 7.8 85 93 0.003 7.8 90 93 Papain 0.33 7.8 66 77 The inhibitory

FcFusionProteinSeparation

Height Width Tailing % min5 10 15 20 25 30 35 40 mAU 0 10 20 30 40 50 60 19 .0 98